Horizon Pharma price target raised to $18 from $16 at JMP Securities JMP Securities increased its price target on Horizon as the firm reports that the company's Vimovo drug is outpacing the firm's early expectations. The firm thinks the company could increase its 2014 guidance on its upcoming Q4 earnings call. JMP Securities expects the stock to rise following the earnings, and recommends owning the shares ahead of the results. It reiterates an Outperform rating on the shares.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.